Furthermore, finding the proper combination such as combined with immunotherapies (such as anti-PD1, anti-PD-L1, and anti-CTLA4), targeting drugs, chemotherapies etc. may be the best approach to increase the anti-tumor effectiveness of GSK126 and other EZH2 inhibitors (42). The gene discussed is EZH2; the disease is neoplasm.